Second Life Therapeutics is developing SL-28, an allogeneic, non-genetically modified cell-based therapy for the treatment of advanced solid tumours. The company has recently demonstrated a novel, non-genetic approach to modulate immune cell activity through targeted manipulation of the Universal Receptive System. The purpose of this open label, multi-center clinical trial is to evaluate the anti-tumor activity, safety, and pharmacokinetics, single-agent SL-28 in patients with a diverse array of solid tumors. The study includes an initial Phase 1 dose escalation to determine recommended dose(s) for expansion of SL-28 as a monotherapy and Phase 2 expansion cohorts. The study will enroll patients with advanced solid tumours, including those who failed previous lines of chemo- and immunotherapies.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of participants with treatment-emergent adverse events
Timeframe: 12 weeks
To evaluate the safety and tolerability of SL-28 by determining the incidence of dose-limiting toxicitieswithin the first 28 days after infusion.
Timeframe: 12 weeks
Change from baseline in ECG QT interval
Timeframe: 12 weeks
Change from baseline in vital signs
Timeframe: 12 weeks
Change from baseline in vital signs
Timeframe: 12 weeks
Change from baseline in vital signs
Timeframe: 12 weeks
Number of participants with dose-limiting toxicities (DLTs)
Timeframe: 12 weeks